Submit Deal

Announced

16 Oct 2023

Completed

10 Nov 2023

ZQ Capital completed the acquisition of Allergy Therapeutics for £48m.

Synopsis

ZQ Capital, an investment firm, completed the acquisition of Allergy Therapeutics, a specialty pharmaceutical company focused upon the diagnosis and treatment of allergy, for £48m.

Principals

target

Allergy Therapeutics

bidder

Zq Capital

Show Details & Financials

Did you work on this deal?

Showcase your expertise to over 3 million dealmakers and industry leaders on Datasite.

Market Context

Sort

Seller Team (9)

manuel llobet

CEO at ALLERGY THERAPEUTICS

Manager

target

Deal

£ 48 M

Total Value

shaun furlong

CFO at ALLERGY THERAPEUTICS

Manager

target

Deal

£ 48 M

Total Value

emma earl

Managing Director at Panmure Gordon & Co

Financial Advisor

target

Deals

£ 1.85 B

Total Value

mark rogers

Associate at Panmure Gordon & Co

Financial Advisor

target

Deals

£ 998 M

Total Value

freddy crossley

Head of Healthcare at Panmure Gordon & Co

Financial Advisor

target

Deals

£ 2.85 B

Total Value

rupert dearden

Managing Director at Panmure Gordon & Co

Financial Advisor

target

Deals

£ 2.00 B

Total Value

alan montgomery

Partner at Herbert Smith Freehills

Lawyer

target

Deals

£ 8.21 B

Total Value

mark bardell

Partner at Herbert Smith Freehills

Lawyer

target

Deals

£ 58.90 B

Total Value

savannah van dongen

Associate at Herbert Smith Freehills

Lawyer

target

Deals

£ 489 M

Total Value

Bidder Team (3)

zheqing (simon) shen

CEO at ZQ CAPITAL

Manager

bidder

Deal

£ 48 M

Total Value

henrik persson

Head of PLC Advisory at Cavendish Corporate Finance

Financial Advisor

bidder

Deals

£ 3.93 B

Total Value

seamus fricker

Associate Director at Cavendish Corporate Finance

Financial Advisor

bidder

Deals

£ 1.47 B

Total Value

By continuing, you agree to our Terms & Conditions and our Data Privacy Policy